Moreover, mutations in BRCA1/2 genes due to several mechanisms, such as germline mutations, somatic mutations, and epigenetic silencing, are present in 33% of ovarian carcinoma samples [7]. This evidence concerns the gene BRCA1 and ovarian carcinoma.